Mechanisms of Ovarian Cancer-Associated Cachexia

Cancer-associated cachexia occurs in 50% to 80% of cancer patients and is responsible for 20% to 30% of cancer-related deaths. Cachexia limits survival and treatment outcomes, and is a major contributor to morbidity and mortality during cancer. Ovarian cancer is one of the leading causes of cancer-r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Endocrinology (Philadelphia) Ročník 165; číslo 1
Hlavní autoři: Callaway, Chandler S, Mouchantat, Lila M, Bitler, Benjamin G, Bonetto, Andrea
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.01.2024
Témata:
Animals
Cachexia - etiology
Female
Humans
Inflammation - pathology
Mice
Muscle, Skeletal - pathology
Muscular Atrophy - etiology
Neoplasms - pathology
Ovarian Neoplasms - complications
Ovarian Neoplasms - pathology
animal models
skeletal muscle
ovarian cancer
cachexia
survival
ISSN:1945-7170, 1945-7170
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Cancer-associated cachexia occurs in 50% to 80% of cancer patients and is responsible for 20% to 30% of cancer-related deaths. Cachexia limits survival and treatment outcomes, and is a major contributor to morbidity and mortality during cancer. Ovarian cancer is one of the leading causes of cancer-related deaths in women, and recent studies have begun to highlight the prevalence and clinical impact of cachexia in this population. Here, we review the existing understanding of cachexia pathophysiology and summarize relevant studies assessing ovarian cancer-associated cachexia in clinical and preclinical studies. In clinical studies, there is increased evidence that reduced skeletal muscle mass and quality associate with worse outcomes in subjects with ovarian cancer. Mouse models of ovarian cancer display cachexia, often characterized by muscle and fat wasting alongside inflammation, although they remain underexplored relative to other cachexia-associated cancer types. Certain soluble factors have been identified and successfully targeted in these models, providing novel therapeutic targets for mitigating cachexia during ovarian cancer. However, given the relatively low number of studies, the translational relevance of these findings is yet to be determined and requires more research. Overall, our current understanding of ovarian cancer-associated cachexia is insufficient and this review highlights the need for future research specifically aimed at exploring mechanisms of ovarian cancer-associated cachexia by using unbiased approaches and animal models representative of the clinical landscape of ovarian cancer.
AbstractList Cancer-associated cachexia occurs in 50% to 80% of cancer patients and is responsible for 20% to 30% of cancer-related deaths. Cachexia limits survival and treatment outcomes, and is a major contributor to morbidity and mortality during cancer. Ovarian cancer is one of the leading causes of cancer-related deaths in women, and recent studies have begun to highlight the prevalence and clinical impact of cachexia in this population. Here, we review the existing understanding of cachexia pathophysiology and summarize relevant studies assessing ovarian cancer-associated cachexia in clinical and preclinical studies. In clinical studies, there is increased evidence that reduced skeletal muscle mass and quality associate with worse outcomes in subjects with ovarian cancer. Mouse models of ovarian cancer display cachexia, often characterized by muscle and fat wasting alongside inflammation, although they remain underexplored relative to other cachexia-associated cancer types. Certain soluble factors have been identified and successfully targeted in these models, providing novel therapeutic targets for mitigating cachexia during ovarian cancer. However, given the relatively low number of studies, the translational relevance of these findings is yet to be determined and requires more research. Overall, our current understanding of ovarian cancer-associated cachexia is insufficient and this review highlights the need for future research specifically aimed at exploring mechanisms of ovarian cancer-associated cachexia by using unbiased approaches and animal models representative of the clinical landscape of ovarian cancer.
Cancer-associated cachexia occurs in 50% to 80% of cancer patients and is responsible for 20% to 30% of cancer-related deaths. Cachexia limits survival and treatment outcomes, and is a major contributor to morbidity and mortality during cancer. Ovarian cancer is one of the leading causes of cancer-related deaths in women, and recent studies have begun to highlight the prevalence and clinical impact of cachexia in this population. Here, we review the existing understanding of cachexia pathophysiology and summarize relevant studies assessing ovarian cancer-associated cachexia in clinical and preclinical studies. In clinical studies, there is increased evidence that reduced skeletal muscle mass and quality associate with worse outcomes in subjects with ovarian cancer. Mouse models of ovarian cancer display cachexia, often characterized by muscle and fat wasting alongside inflammation, although they remain underexplored relative to other cachexia-associated cancer types. Certain soluble factors have been identified and successfully targeted in these models, providing novel therapeutic targets for mitigating cachexia during ovarian cancer. However, given the relatively low number of studies, the translational relevance of these findings is yet to be determined and requires more research. Overall, our current understanding of ovarian cancer-associated cachexia is insufficient and this review highlights the need for future research specifically aimed at exploring mechanisms of ovarian cancer-associated cachexia by using unbiased approaches and animal models representative of the clinical landscape of ovarian cancer.Cancer-associated cachexia occurs in 50% to 80% of cancer patients and is responsible for 20% to 30% of cancer-related deaths. Cachexia limits survival and treatment outcomes, and is a major contributor to morbidity and mortality during cancer. Ovarian cancer is one of the leading causes of cancer-related deaths in women, and recent studies have begun to highlight the prevalence and clinical impact of cachexia in this population. Here, we review the existing understanding of cachexia pathophysiology and summarize relevant studies assessing ovarian cancer-associated cachexia in clinical and preclinical studies. In clinical studies, there is increased evidence that reduced skeletal muscle mass and quality associate with worse outcomes in subjects with ovarian cancer. Mouse models of ovarian cancer display cachexia, often characterized by muscle and fat wasting alongside inflammation, although they remain underexplored relative to other cachexia-associated cancer types. Certain soluble factors have been identified and successfully targeted in these models, providing novel therapeutic targets for mitigating cachexia during ovarian cancer. However, given the relatively low number of studies, the translational relevance of these findings is yet to be determined and requires more research. Overall, our current understanding of ovarian cancer-associated cachexia is insufficient and this review highlights the need for future research specifically aimed at exploring mechanisms of ovarian cancer-associated cachexia by using unbiased approaches and animal models representative of the clinical landscape of ovarian cancer.
Author Bonetto, Andrea
Mouchantat, Lila M
Bitler, Benjamin G
Callaway, Chandler S
Author_xml – sequence: 1
  givenname: Chandler S
  orcidid: 0000-0002-4562-0508
  surname: Callaway
  fullname: Callaway, Chandler S
  organization: Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
– sequence: 2
  givenname: Lila M
  surname: Mouchantat
  fullname: Mouchantat, Lila M
  organization: Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
– sequence: 3
  givenname: Benjamin G
  orcidid: 0000-0002-5809-5271
  surname: Bitler
  fullname: Bitler, Benjamin G
  organization: Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
– sequence: 4
  givenname: Andrea
  orcidid: 0000-0002-3235-1871
  surname: Bonetto
  fullname: Bonetto, Andrea
  organization: Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37980602$$D View this record in MEDLINE/PubMed
BookMark eNpNj89Lw0AQhRep2B969Sg9eomd2WR3k2MpVoVKL3oOs5MJjTSbNtuK_vcWrODpfTw-HryxGoQuiFK3CA-oEWYSqo77md9Thc5eqBEWmUkcOhj846Eax_gBgFmWpVdqmLoiBwt6pOBVeEOhiW2cdvV0_Ul9Q2G6oMDSJ_MYO27oINWp4Y18NXStLmvaRrk550S9Lx_fFs_Jav30spivEjYaDgnlUJNh5jRz5J048QAF5cYWhLoCzVZb7S0btOCM5FVqrMXMe1t7IdYTdf-7u-u7_VHioWybyLLdUpDuGEudFxoQC3Qn9e6sHn0rVbnrm5b67_Lvpf4Bac5V3A
CitedBy_id crossref_primary_10_1016_j_jep_2024_118811
crossref_primary_10_1016_j_molmet_2025_102211
crossref_primary_10_1186_s13048_024_01519_9
crossref_primary_10_3390_cells13090783
ContentType Journal Article
Copyright The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1210/endocr/bqad176
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1945-7170
ExternalDocumentID 37980602
Genre Research Support, U.S. Gov't, Non-P.H.S
Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAMS NIH HHS
  grantid: R01 AR080051
– fundername: NCI NIH HHS
  grantid: R37CA261987
– fundername: NIAMS NIH HHS
  grantid: R01 AR079379
– fundername: NIAMS NIH HHS
  grantid: T32 AR080630
– fundername: NIAMS NIH HHS
  grantid: AR080630
– fundername: NCI NIH HHS
  grantid: R37 CA261987
– fundername: NIAMS NIH HHS
  grantid: R01AR079379
GroupedDBID ---
-DZ
-~X
.55
.XZ
0R~
18M
29G
2WC
34G
354
39C
4.4
48X
5GY
5RE
5RS
5YH
79B
8F7
AABZA
AACZT
AAIMJ
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
ABDFA
ABEJV
ABGNP
ABHFT
ABJNI
ABLJU
ABMNT
ABNHQ
ABPPZ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ABXZS
ACGFO
ACGFS
ACIWK
ACPRK
ADBBV
ADGKP
ADGZP
ADHKW
ADNBA
ADQBN
ADRTK
ADVEK
AEHZK
AELWJ
AEMDU
AEMQT
AENEX
AENZO
AETBJ
AEWNT
AFFZL
AFGWE
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGORE
AGQXC
AGUTN
AHGBF
AHMBA
AHMMS
AJBYB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALXQX
APIBT
ARIXL
ATGXG
BAWUL
BAYMD
BCRHZ
BEYMZ
BPHCQ
BSWAC
BTRTY
BVXVI
C45
CDBKE
CGR
CJ0
CS3
CUY
CVF
DAKXR
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
EMOBN
ENERS
F5P
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
HF~
HZ~
IAO
IH2
IHR
ITC
KOP
KQ8
KSI
KSN
L7B
LMP
M5~
MHKGH
MJL
NLBLG
NOMLY
NOYVH
NPM
O9-
OAUYM
OBH
ODMLO
OFXIZ
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
PQQKQ
PROAC
Q-A
REU
ROX
ROZ
TEORI
TJX
TLC
TR2
TWZ
UPT
VVN
W2D
W8F
WH7
WOQ
X7M
YBU
YHG
YOC
YSK
ZCA
ZY1
7X8
ABUFD
ID FETCH-LOGICAL-c520t-a80fa5ccc347ab7e7eb009a8569a12d02c6262b6c516075e8d356614bb6fbeac2
IEDL.DBID 7X8
ISICitedReferencesCount 8
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001115827600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1945-7170
IngestDate Sun Nov 09 13:53:22 EST 2025
Sat Sep 20 02:12:24 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords animal models
skeletal muscle
ovarian cancer
cachexia
survival
Language English
License The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c520t-a80fa5ccc347ab7e7eb009a8569a12d02c6262b6c516075e8d356614bb6fbeac2
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0002-3235-1871
0000-0002-4562-0508
0000-0002-5809-5271
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/10699881
PMID 37980602
PQID 2892011917
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2892011917
pubmed_primary_37980602
PublicationCentury 2000
PublicationDate 2024-01-01
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Endocrinology (Philadelphia)
PublicationTitleAlternate Endocrinology
PublicationYear 2024
SSID ssj0014443
Score 2.4822423
SecondaryResourceType review_article
Snippet Cancer-associated cachexia occurs in 50% to 80% of cancer patients and is responsible for 20% to 30% of cancer-related deaths. Cachexia limits survival and...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
SubjectTerms Animals
Cachexia - etiology
Female
Humans
Inflammation - pathology
Mice
Muscle, Skeletal - pathology
Muscular Atrophy - etiology
Neoplasms - pathology
Ovarian Neoplasms - complications
Ovarian Neoplasms - pathology
Title Mechanisms of Ovarian Cancer-Associated Cachexia
URI https://www.ncbi.nlm.nih.gov/pubmed/37980602
https://www.proquest.com/docview/2892011917
Volume 165
WOSCitedRecordID wos001115827600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qRLz4sfkxv6gg3sLSNGmak4zh8LK5g8JuJUkT2MF2W-fQ_96XtmMnQfDSQ2hD-_L63vu9T4QesjAzJgOkyoVimGnOsVYhx5F2UhDpi8JdNWxCjMfJdConjcOtbNIqNzKxEtRZYbyPvAfAwOsqQBdP8wX2U6N8dLUZobGLWhGYMp6rxXQbRWCsTrCXjGOALaRp2uirVmwOGy97eqGyUMS_m5eVmhke__cFT9BRY2AG_ZojTtGOzduo088BXH98B49BlfJZ-dLb6GDURNY7iIysrwGelR9lULjgdQ0YWuXBwDPFEm8O0WawAsf8NVNn6H34_DZ4wc00BWw4JSusEuIUN8ZETCgtrPBTg6RKeCxVSDNCDWAbqmPDfc85bpMs4l55ax07DeKZnqO9vMjtJQocfCajInQ6Ukw6uIMbK7W2VqiYGtlF9xsSpcCtPgShclt8lumWSF10UdM5nddtNdJIyITEhF794elrdEjBuqh9ITeo5eBftbdo36xXs3J5V7EBXMeT0Q8JIL0S
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanisms+of+Ovarian+Cancer-Associated+Cachexia&rft.jtitle=Endocrinology+%28Philadelphia%29&rft.au=Callaway%2C+Chandler+S&rft.au=Mouchantat%2C+Lila+M&rft.au=Bitler%2C+Benjamin+G&rft.au=Bonetto%2C+Andrea&rft.date=2024-01-01&rft.eissn=1945-7170&rft.volume=165&rft.issue=1&rft_id=info:doi/10.1210%2Fendocr%2Fbqad176&rft_id=info%3Apmid%2F37980602&rft_id=info%3Apmid%2F37980602&rft.externalDocID=37980602
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1945-7170&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1945-7170&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1945-7170&client=summon